Understanding MOG antibody-associated disease in Brazil
- PMID: 38035577
- PMCID: PMC10689110
- DOI: 10.1055/s-0043-1777298
Understanding MOG antibody-associated disease in Brazil
Conflict of interest statement
DC: Regular visits from Biogen, Merck, Novartis, EMS, Horizon, and Alexion. Member of the Organizing Committee of the Brazilian Committee on Treatment in Multiple Sclerosis (BCTRIMS); GDS: Regular visits from Biogen, Merck, Novartis, EMS, Horizon, and Alexion.
Comment on
-
Clinical spectrum of myelin oligodendrocyte glycoprotein antibody-associated disease in Brazil: a single-center experience.Arq Neuropsiquiatr. 2023 Nov;81(11):980-988. doi: 10.1055/s-0043-1777002. Epub 2023 Nov 30. Arq Neuropsiquiatr. 2023. PMID: 38035583 Free PMC article.
References
-
- Terrim S, Silva G D, de Sá E Benevides Falcao F C et al.Real-world application of the 2022 diagnostic criteria for first-ever episode of optic neuritis. J Neuroimmunol. 2023;381:578140. - PubMed
-
- Silva G D, Apóstolos-Pereira S L, Callegaro D. Estimated prevalence of AQP4 positive neuromyelitis optica spectrum disorder and MOG antibody associated disease in São Paulo, Brazil. Mult Scler Relat Disord. 2023;70:104488. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources